To identify the percentage of genomic defects in components of antigen presentation machinery and immune response regulation in MSI-H CRCs, we analysed series of truncating or oncogenic mutations in B2M, PTEN, JAK1, JAK2, STK11 and EGFR, that were previously reported to be associated with immune checkpoint inhibitor resistance and identified 46.7% of TMB-high CRC harboured at least one oncogenic mutation in those genes that may lead to immune checkpoint inhibitor resistance (Fig. 2d). The gene discussed is EGFR; the disease is colorectal carcinoma.